Repligen (RGEN) Stock Forecast & Price Target

$144.46 -2.08 (-1.42%)

(As of 12/20/2024 05:31 PM ET)

Repligen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
5

Buy
8

Based on 13 Wall Street analysts who have issued ratings for Repligen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 5 have given a hold rating, and 8 have given a buy rating for RGEN.

Consensus Price Target

$185.20
28.20% Upside

According to the 13 analysts' twelve-month price targets for Repligen, the average price target is $185.20. The highest price target for RGEN is $220.00, while the lowest price target for RGEN is $155.00. The average price target represents a forecasted upside of 28.20% from the current price of $144.46.

Get the Latest News and Ratings for RGEN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Repligen and its competitors.

RGEN Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)
Hold	5 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$185.20	$190.25	$188.38	$192.27
Forecasted Upside	28.20% Upside	34.56% Upside	31.76% Upside	5.23% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Your chance to get on the next “60-Second Trade” (Ad)

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Just head over here!

RGEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RGEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Repligen Stock vs. The Competition

Type	Repligen	Medical Companies	S&P 500
Consensus Rating Score	2.62	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.20% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent RGEN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/17/2024	Canaccord Genuity Group 5 of 5 stars	K. Mikson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$165.00	+2.54%
11/14/2024	Wolfe Research 3 of 5 stars	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
9/26/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$205.00 ➝ $205.00	+37.81%
8/27/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$180.00	+23.26%
8/5/2024	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
7/31/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$190.00 ➝ $200.00	+18.34%
This Indicator called BOTH NVDA rallies (Ad) Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here.
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$205.00 ➝ $185.00	+9.86%
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$170.00 ➝ $170.00	+9.30%
6/26/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00 ➝ $155.00	+25.86%
6/18/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
2/22/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$165.00 ➝ $207.00	+6.84%
2/15/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$210.00 ➝ $220.00	+6.10%
8/3/2023	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$207.00 ➝ $200.00	+16.73%
1/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$230.00 ➝ $200.00	+28.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:41 PM ET.

RGEN Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Repligen is $185.20, with a high forecast of $220.00 and a low forecast of $155.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
: According to analysts, Repligen's stock has a predicted upside of 28.20% based on their 12-month stock forecasts.
: Repligen has been rated by research analysts at Canaccord Genuity Group, Canaccord Genuity Group, Royal Bank of Canada, and Wolfe Research in the past 90 days.
: Analysts like Repligen less than other "medical" companies. The consensus rating score for Repligen is 2.62 while the average consensus rating score for "medical" companies is 2.81. Learn more on how RGEN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Your chance to get on the next “60-Second Trade” (Ad)

Just head over here!

This page (NASDAQ:RGEN) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Stock Forecast & Price Target